Mizuho analyst Mara Goldstein raised the firm’s price target on Kura Oncology to $32 from $26 and keeps a Buy rating on the shares. The KOMET-007 data release showed the emergence of validation for Kura’s thesis that ziftomenib combined with standard of care can reduce differentiation syndrome events, facilitate activity and widen the addressable market opportunity, the analyst tells investors in a research note. As a result, the firm increased its probability of success in its model to 80% from 75%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KURA:
- Kura Oncology’s KOMET-007 Trial Shows Promising Results
- Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
- Kura Oncology to hold a virtual investor event
- Kura Oncology Announces Private Placement Details
- Kura Oncology Executes Unregistered Equity Securities Sale
